{
  "id": 1769615071565,
  "seqId": 130,
  "title": "Chorioretinal Dystrophies & Retinal Toxicities: Clinical Compendium",
  "summary": "An exhaustive clinical guide to inherited chorioretinal conditions, albinism phenotypes, and drug-induced retinal toxicities. This resource covers pathophysiology, diagnostic investigations, and management protocols for potentially blinding disorders.",
  "date": "2026-01-28T15:44:31.565Z",
  "data": {
    "title": "Chorioretinal Dystrophies & Retinal Toxicities: Clinical Compendium",
    "summary": "An exhaustive clinical guide to inherited chorioretinal conditions, albinism phenotypes, and drug-induced retinal toxicities. This resource covers pathophysiology, diagnostic investigations, and management protocols for potentially blinding disorders.",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><circle cx='50' cy='50' r='45' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><circle cx='50' cy='50' r='10' fill='hsl(215, 90%, 45%)'/><path d='M20 50 Q50 20 80 50 Q50 80 20 50' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='1'/><path d='M30 30 L40 40 M70 30 L60 40 M30 70 L40 60 M70 70 L60 60' stroke='hsl(215, 90%, 45%)' stroke-width='2'/></svg>",
    "sections": [
      {
        "title": "Overview: Chorioretinal Dystrophies",
        "icon": "visibility",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "These are inherited potentially blinding conditions, in which there is progressive chorioretinal atrophy; often initially involving the RPE, choriocapillaris, and photoreceptors, and in later stages, the larger choroidal vessels."
      },
      {
        "title": "Gyrate Atrophy",
        "icon": "rebase_edit",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "center": "Gyrate Atrophy (AR)",
          "branches": [
            "Genetics: OAT gene mutation (ornithine aminotransferase); cofactor B6",
            "Pathophysiology: Failure to catalyze conversion of ornithine to glutamic-γ-semialdehyde and proline",
            "Demographics: Commoner in Finland; symptoms from late childhood",
            "Clinical Subtypes: B6 (pyridoxine) responsive vs non-responsive"
          ]
        }
      },
      {
        "title": "Gyrate Atrophy: Clinical Profile",
        "icon": "clinical_notes",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Symptoms: Nyctalopia, peripheral field loss, later dVA",
          "Fundus: Well-defined, circular RPE/choroidal atrophy patches (mid-peripheral/superficial)",
          "Progression: Atrophic areas coalesce towards posterior pole; characteristic scalloped leading edge; deeper atrophy",
          "Complications: ERM, CMO, moderate to high myopia, posterior subcapsular cataract"
        ]
      },
      {
        "title": "Gyrate Atrophy: Investigations & Tx",
        "icon": "biotech",
        "type": "table",
        "layout": "half_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Category",
            "Details"
          ],
          "rows": [
            [
              "Plasma Ornithine",
              "10–15× normal level; also elevated in urine and CSF"
            ],
            [
              "ERG",
              "Early reduction (rods > cones); less marked in B6-responsive group"
            ],
            [
              "OCT",
              "Multiple intraretinal cystoid spaces, linear hyperreflective GCL deposits, outer retinal tubulations"
            ],
            [
              "Treatment 1",
              "Pyridoxine (B6) supplements (for responsive minority)"
            ],
            [
              "Treatment 2",
              "Arginine-restricted diet (for non-responders)"
            ],
            [
              "Treatment 3",
              "Proline supplementation (may slow progress)"
            ]
          ]
        }
      },
      {
        "title": "Choroideraemia",
        "icon": "male",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "purple",
        "content": [
          "Inheritance: XL condition (CHM gene; encodes Rab escort protein-1 (REP1))",
          "Affected: Significant impairment from childhood in males (♂)",
          "Females: ♀ carriers usually asymptomatic; show widespread fine RPE atrophy and mid-peripheral granular pigment",
          "Symptoms: Nyctalopia, concentric VF loss, dVA variable (often middle age)",
          "Fundus Progression: Patchy mid-peripheral superficial atrophy -> central diffuse deeper atrophy exposing sclera",
          "NB: Relative sparing of retinal vessels and optic disc is characteristic",
          "Associated: Posterior subcapsular cataract, early vitreous degeneration",
          "Investigations: ERG reduction (rods > cones)",
          "Management: Supportive treatment, genetic counselling, prenatal testing, Phase II gene therapy studies pending"
        ]
      },
      {
        "title": "Choroideraemia Differential Diagnosis",
        "icon": "rule",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Severe XL RP",
          "Bietti’s crystalline dystrophy",
          "Thioridazine toxicity",
          "Advanced Stargardt’s disease (rare)",
          "PRPH2 retinopathy (rare)"
        ]
      },
      {
        "title": "Central Areolar Choroidal Dystrophy",
        "icon": "center_focus_weak",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": "Slowly progressive loss of central vision with symmetric, sharply outlined geographic atrophy. Large choroidal vessels change from reddish-orange to yellow-white ('choroidal sclerosis'). Associated with PRPH2 and GUCY2D mutations."
      },
      {
        "title": "Albinism: General Features",
        "icon": "palette",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "blue",
        "content": [
          "Definition: Abnormalities in melanin synthesis resulting in pigment deficiency",
          "Ocular Albinism: Eye alone",
          "Oculocutaneous Albinism: Eye, skin, and hair",
          "Visual Acuity: Generally reduced due to foveal hypoplasia",
          "Chiasm: Increased decussation of temporal fibres; demonstrated by VEP contralateral predominance"
        ]
      },
      {
        "title": "Ocular Albinism (OA)",
        "icon": "visibility_off",
        "type": "mindmap",
        "layout": "half_width",
        "color_theme": "blue",
        "content": {
          "center": "Nettleship–Falls (XL)",
          "branches": [
            "Genetics: OA1 gene (melanosome function)",
            "Clinical: dVA, photophobia, nystagmus, strabismus, ametropia",
            "Fundus: Hypopigmentation, foveal hypoplasia, iris transillumination",
            "Female Carriers: Patchy 'mud-splattered' fundus",
            "OCT: Bulging photoreceptor nuclear layer; absent foveal depression; persistent inner retinal layers",
            "Treatment: Correct ametropia (tinted lenses), prevent amblyopia, strabismus/nystagmus surgery"
          ]
        }
      },
      {
        "title": "Oculocutaneous Albinism (OCA)",
        "icon": "person",
        "type": "table",
        "layout": "half_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Type",
            "Mechanism/Gene"
          ],
          "rows": [
            [
              "Type I",
              "Tyrosinase (Chr 11q)"
            ],
            [
              "Type II",
              "P product (Chr 15q; transporter)"
            ],
            [
              "Type III",
              "Tyrosinase-related protein 1 (Chr 9p)"
            ],
            [
              "Systemic Associations",
              "Variable skin/hair hypopigmentation (blond)"
            ],
            [
              "Hermansky–Pudlak",
              "Mild OCA, low platelets, pulmonary/renal/intestinal issues (Puerto Rican ancestry)"
            ],
            [
              "Chediak–Higashi",
              "Mild OCA, leucocyte abnormalities, recurrent pyogenic infections"
            ],
            [
              "Testing",
              "Hair bulb incubation test (after age 5y)"
            ]
          ]
        }
      },
      {
        "title": "Toxic Retinopathy: CQ & HCQ",
        "icon": "warning",
        "type": "red_flag",
        "layout": "full_width",
        "color_theme": "red",
        "content": [
          "Chloroquine (CQ) Risk: >2.3mg/kg real weight or >3.5mg/kg/d (historical)",
          "Hydroxychloroquine (HCQ) Risk: >5.0mg/kg real weight or >6.5mg/kg/d (historical)",
          "Risk Factors: Duration (>5y), renal function, pre-existing maculopathy, tamoxifen use",
          "Clinical Sign: 'Bull’s eye maculopathy' (depigmentation ring)",
          "East Asian Pattern: May show extramacular toxicity",
          "Irreversibility: Toxicity is irreversible; CQ is higher risk than HCQ"
        ]
      },
      {
        "title": "HCQ/CQ Screening (AAO 2016 Guidelines)",
        "icon": "event_repeat",
        "type": "chart",
        "layout": "half_width",
        "color_theme": "red",
        "content": {
          "type": "bar",
          "data": [
            {
              "label": "Risk <5 years",
              "value": 1
            },
            {
              "label": "Risk <10 years",
              "value": 2
            },
            {
              "label": "Risk @ 20 years",
              "value": 20
            }
          ]
        }
      },
      {
        "title": "HCQ/CQ Diagnostic Findings",
        "icon": "image",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Symptoms: Asymptomatic initially, paracentral scotomas, dVA, d color vision",
          "OCT: Subtle loss of ellipsoid zone -> parafoveal thinning of ONL -> widespread RPE atrophy",
          "FAF: Increased autofluorescence ring -> parafoveal hypoautofluorescence",
          "FFA: RPE window defects; minimal choriocapillaris loss",
          "mfERG: Reduced pericentral hexagon amplitudes",
          "Cornea: Vortex keratopathy, enhanced Hudson-Stahli line"
        ]
      },
      {
        "title": "Box 13.7: Mechanisms of Drug Toxicity",
        "icon": "settings",
        "type": "table",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "headers": [
            "Mechanism",
            "Drugs Involved"
          ],
          "rows": [
            [
              "RPE/Retina Degeneration",
              "CQ/HCQ, Phenothiazines, Desferrioxamine, Clofazimine, Didanosine (DDI), Quinine, Ritonavir"
            ],
            [
              "Retinal Vasculopathy",
              "IFN retinopathy, Aminoglycoside antibiotics, Talc retinopathy"
            ],
            [
              "CMO",
              "Nicotinic acid, Topical adrenaline, PgAs (latanoprost), Paclitaxel, Glitazones, Fingolimod"
            ],
            [
              "Crystalline Retinopathy",
              "Talc, Tamoxifen, Canthaxanthin, Nitrofurantoin, Methoxyflurane, Ritonavir"
            ],
            [
              "Retinal Folds",
              "Topiramate and other sulfamated drugs"
            ]
          ]
        }
      },
      {
        "title": "Phenothiazines & Desferrioxamine",
        "icon": "medication",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Thioridazine: Toxicity if >1g/d for weeks; nummular RPE loss, pigment plaques, optic atrophy",
          "Chlorpromazine: Corneal/lens deposits; pigmentary changes rarer (requires massive dose ~2400mg/d)",
          "Desferrioxamine: Chelating agent; no 'safe' dose; RPE changes central/peripheral within weeks",
          "Deferasirox: Orally active agent; may also lead to retinopathy"
        ]
      },
      {
        "title": "Specific Toxicities (Part 2)",
        "icon": "healing",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Interferon alfa: Microangiopathy (CWS, haemorrhages); risk in diabetics/hypertensive",
          "Aminoglycosides (Gentamicin): Acute macular necrosis, vascular non-perfusion, NVG (post-intravitreal)",
          "Talc: Crystals in end-arterioles (IV drug use); ischaemic retinopathy, NV, VH",
          "Nicotinic Acid: CMO without vascular leakage (>1.5g/d); toxic effect on Müller cells",
          "Tamoxifen: White crystals, CMO, RPE changes; risk if cumulative dose >100g or high daily dose"
        ]
      },
      {
        "title": "Specific Toxicities (Part 3)",
        "icon": "science",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Canthaxanthine: Ring-shaped yellow-orange crystals; usually asymptomatic; clears on discontinuation",
          "Topiramate: Acute myopia, AC shallowing, ciliary body swelling, retinal folds, AACG",
          "MEK Inhibitors: Transient SRF (serous retinal fluid); not usually a reason to stop cancer Tx",
          "Poppers (Alkyl Nitrite): Foveal yellow spots, disruption of cone outer segments on OCT",
          "Fingolimod: Macular oedema (most frequent), haemorrhages, RVO",
          "Taxanes (Paclitaxel/Docetaxel): CMO/macular oedema without leakage",
          "HIV Drugs: Didanosine (peripheral atrophy); Ritonavir (central epitheliopathy, MacTel, crystals)"
        ]
      },
      {
        "title": "Box 13.8: Causes of Crystalline Retinopathy",
        "icon": "diamond",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Vascular: Type 2 idiopathic MacTel",
          "Drugs: Tamoxifen, Canthaxanthine, Methoxyflurane, Talc, Nitrofurantoin, Ritonavir",
          "Inherited: Bietti’s, Kjellin syndrome, Sjögren–Larsson, Oxalosis, Cystinosis",
          "Other: West African crystalline maculopathy"
        ]
      },
      {
        "title": "Miscellaneous: Flecked Retina & Solar",
        "icon": "wb_sunny",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "purple",
        "content": [
          "Flecked Retina: Originally Fundus albipunctatus, flavimaculatus, familial drusen, Kandori. Now includes Alport, Metabolic (cystinosis), Vit A deficiency",
          "Solar Maculopathy: Photochemical injury from sun/eclipse; oxidative stress; small yellow-white foveolar lesions",
          "Solar/Laser OCT: Characteristic defect in IS-OS junction at fovea ('microhole' or 'outer retinal hole')",
          "Laser Pointer Maculopathy: Discrete IS-OS line abnormalities; horizontal/vertical linear patterns if self-inflicted; 2° iris atrophic changes",
          "Acute Macular Neuroretinopathy (AMN): Wedge-shaped dark lesions pointing to fovea (best on IR reflectance); OCT shows OPL/ONL hyperreflectivity"
        ]
      }
    ],
    "chapterId": "paediatric"
  },
  "chapterId": "paediatric",
  "_newlyImported": 1769615071565,
  "communityId": "sub_1769614749293_o782a218bpeoiw",
  "communityAuthor": "hh",
  "communityDate": "2026-01-28T15:39:09.293Z",
  "_serverSynced": true
}